Medicus Pharma's SkinJect Phase 2 Hits 80% ORR, Aims to Reduce Skin Cancer Surgeries
MDCX sits 30% above its 52-week low of $0.37 on light trading volume (0.4× avg).
Summary
Medicus Pharma Ltd. announced an 80% Overall Response Rate (ORR) in the 200µg cohort of its Phase 2 SkinJect study for non-melanoma skin cancer, alongside 73% clinical clearance and 40% histological complete response. The company will host a business update call to elaborate on these results and its new AI-enabled drug development plan, which aims to streamline clinical development. This detailed update builds upon yesterday's announcement of positive topline Phase 2 data, providing more specific and robust efficacy numbers, particularly the 80% ORR. While highly positive for the drug's prospects, this news arrives shortly after the company received a going concern warning from its auditors, highlighting severe financial distress. The strong clinical data is material for a company with a low market cap, potentially offering a significant catalyst by suggesting SkinJect could reduce the need for surgery in many patients. Traders will monitor the upcoming business call for further insights into the data, regulatory strategy, and the company's path forward amidst its financial challenges.
At the time of this announcement, MDCX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6M. The 52-week trading range was $0.37 to $8.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.